Biological Dynamics, Inc discovered new Exo-PDAC, liquid biopsy assay for the early detection of pancreatic ductal adenocarcinoma (PDAC) in high-risk adults.
Globally, pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal forms of cancer.
Exo-PDAC is the first assay using novel alternating current electrokinetic-based technology for early disease detection such as cancer, Alzheimer’s disease, and infectious diseases.
Exo-PDAC requires a small amount of blood from patients to analyse minimal sample preparation or processing.
By 2040, PDAC is expected to be the second common cancer leading to deaths due to the fact that the disease is asymptomatic in its initial stages. Patients undergo diagnosis during advanced stages of disease progression when treatments are limited. Detection of PDAC biomarkers at an early stage would help patients in further disease progression or metastasizes. However, this requires high degree of sensitivity and specificity where conventional laboratory testing methods lack. Early pancreatic cancer detection may save life of many individuals.
U.S. Food and Drug Administration (FDA) grants breakthrough device designation for Exo-PDAC, early-stage pancreatic cancer detection test.
